Search Results
Feb 23, 2026, 07:00 ET NG ENERGY ANNOUNCES YEAR-END RESERVES AND RESOURCES AND COMMENCEMENT OF DRILLING OF HECHICERO-1X AT SINU-9
ConchitaSinu-9The report entitled "Detailed Property Report - Sinu-9 Block, Colombia - Evaluation of the P&NG Reserves and Resources of NG Energy International" (the "Sinu-9 Report") was prepared by Sproule ERCE with an effective date of December 31, 2025 and a preparation
More news about: NG Energy International Corp.
Feb 21, 2026, 08:00 ET TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
Accessed February 2026.13 Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The
More news about: Johnson & Johnson
Feb 21, 2026, 01:57 ET 私補市場2026新趨勢｜補習平台分享上門補習價錢2026及揀補習導師三大常見中伏位及貼士
https://drive.google.com/file/d/1dPd5xuHeVG4mfH7rbJ0FABIdhDbOG6nG/view?usp=sharing 上門補習收費 2026: 一般學科補習（英文科除外）
More news about: Tutor Circle Limited
Feb 20, 2026, 22:00 ET 私補市場2026新趨勢｜補習平台分享上門補習價錢2026及揀補習導師三大常見中伏位及貼士
https://drive.google.com/file/d/1dPd5xuHeVG4mfH7rbJ0FABIdhDbOG6nG/view?usp=sharing 上門補習收費 2026: 一般學科補習（英文科除外）
More news about: Tutor Circle Limited
Feb 20, 2026, 19:42 ET NATIONAL GEOGRAPHIC-LINDBLAD EXPEDITIONS' TRAVELERS HELP BRING GIANT TORTOISES BACK TO FLOREANA ISLAND
discovery brand National Geographic and the pioneer of modern expedition cruising Lindblad Expeditions. The Lindblad Expeditions-National Geographic (LEX-NG) Fund supports projects to understand and protect our world's ocean, restore critical marine and coastal habitats, and foster environmental stewardship
More news about: National Geographic-Linblad Expeditions
Feb 19, 2026, 11:19 ET LANZAJET GIBT 47 MIO. $ NEUES KAPITAL UND DEN ABSCHLUSS EINER ERSTEN KAPITALRUNDE MIT EINER BEWERTUNG VON 650 MIO. $ VOR DEM KAPITAL BEKANNT - WEITERE VALIDIERUNG DER SAF-TECHNOLOGIE VON LANZAJET UND ERMÖGLICHUNG VON WACHSTUM
lrunde-mit-einer-bewertung-von-650-mio--vor-dem-kapital-bekannt---weitere-validierung-der-saf-technologie-von-lanzajet-und-ermoglichung-von-wachstum-302692829.html
More news about: LanzaJet, Inc.
Feb 19, 2026, 08:49 ET Parents Anonymous® Community & Family Resource Center Partners with Local Organizations to Deliver Essential Food Support to Chinatown Families
Chinatown Service Center to partner with Parents Anonymous and God's Pantry on today's food distribution to 300 residents in Chinatown," said Peter Ng, President and CEO of Chinatown Service Center. "Food insecurity hits in many low-income areas, including Chinatown. The food received today will help
More news about: Parents Anonymous
Feb 18, 2026, 22:34 ET FDA 向兩項針對關鍵耐藥病原體的快速檢測授予「突破性醫療器械」認定
年），由於其耐藥特性及在醫療環境中的快速傳播能力，被視為最危險的院內感染細菌之一。NG-TEST®Candida auris 是首款專門為識別耳念珠菌 (C. auris) 而設計的快速側向流免疫分析試劑，僅需 15 分鐘即可完成培養樣本的鑑定。 已發表的數據顯示，該試劑對多種分離菌株的檢測結果，與參考標準方法達到 100% 的一致性，充分支持其在爆發調查及感染控制中所扮演的角色。NG-TEST®Acineto-5® 可直接從不動桿菌樣本中檢測並區分五大類主要碳青黴烯酶家族——OXA-23-like、OXA-24/143-like、OXA-58-like、VIM
More news about: Hardy Diagnostics
Feb 18, 2026, 21:31 ET FDA, 치명적 약제내성 병원체 표적 신속 검사 2종을 혁신 의료기기로 지정
Diagnostics)가 항생제 내성(Antimicrobial Resistance, AMR)에 대응하는 중대한 진전을 이룬 가운데 미국 식품의약국(Food and Drug Administration, FDA)에서 두 가지 신속 진단 분석법 NG-TEST®Candida auris와 NG-TEST®Acineto-5®을 혁신 의료기기로 지정했다고 2월 18일 발표했다. 이 지정은 생명을 위협하는 질환 및 중대한 미충족 의료 수요를 해결할 잠재력을 지닌 기술을 대상으로 하는 것이다.
More news about: Hardy Diagnostics
Feb 18, 2026, 16:38 ET FDA concede designação de dispositivo inovador a dois testes rápidos que têm como alvo patógenos críticos resistentes a medicamentos
Resistência Antimicrobiana (RAM), a NG Biotech, em parceria com a Hardy Diagnostics, anunciou hoje que a Administração de Alimentos e Medicamentos dos EUA (FDA) concedeu Designações de Dispositivo Inovador para dois ensaios rápidos diagnósticos: NG-TEST®Candida auris e NG-TEST®Acineto-5®.
More news about: Hardy Diagnostics
Feb 18, 2026, 16:34 ET La FDA otorga la designación de dispositivo innovador a dos pruebas rápidas dirigidas a patógenos críticos resistentes a medicamentos
por sus siglas en inglés), NG Biotech, en asociación con Hardy Diagnostics, anunció hoy que la Administración de Alimentos y Medicamentos de EE. UU. (FDA) ha otorgado las designaciones de dispositivos innovadores a dos ensayos de diagnóstico rápido: NG-TEST®Candida auris y NG-TEST®Acineto-5®.
More news about: Hardy Diagnostics
Feb 18, 2026, 16:29 ET La FDA accorde le statut de dispositif innovant à deux tests rapides ciblant des agents pathogènes critiques résistants aux médicaments
antimicrobiens (RAM), NG Biotech, en partenariat avec Hardy Diagnostics, a annoncé aujourd'hui que la Food and Drug Administration (FDA) des États-Unis avait accordé la désignation de dispositif innovant (« Breakthrough Device Designation ») à deux tests de diagnostic rapide : NG-TEST® Candida auris
More news about: Hardy Diagnostics
Feb 18, 2026, 13:03 ET Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF)
and microsatellite instability (MSI).The analytical validation study demonstrated robust and reproducible detection of all supported variant classes using as little as 15 ng of tumor-derived nucleic acid from CSF, with an analytical sensitivity of 96.7% for SNVs and Indels with a 100% limit of detection at a variant allele
More news about: Belay Diagnostics
Feb 18, 2026, 11:52 ET Die FDA erteilt zwei Schnelltests zur Erkennung kritischer arzneimittelresistenter Pathogene den Status Breakthrough Device
Resistenzen (AMR) gab NG Biotech heute in Zusammenarbeit mit Hardy Diagnostics bekannt, dass die U.S. Food and Drug Administration (FDA) zwei Schnelldiagnosetests als Breakthrough Device (bahnbrechendes Medizinprodukt) eingestuft hat: NG-TEST® Candida auris und NG-TEST® Acineto-5®.
More news about: Hardy Diagnostics
Feb 18, 2026, 07:43 ET FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens
Antimicrobial Resistance (AMR), NG Biotech, in partnership with Hardy Diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designations to two rapid diagnostic assays: NG-TEST® Candida auris and NG-TEST® Acineto-5®.
More news about: Hardy Diagnostics
Feb 18, 2026, 07:43 ET FDA 重大な薬剤耐性病原体を標的とする2つの迅速検査にブレイクスルーデバイス指定付与
（CRAB）は、WHOの細菌優先病原体リスト（2024年）に含まれており、耐性プロファイルと医療現場での急速な感染により、最も危険な院内感染菌のひとつです。NG-TEST® カンジダ・アウリスは、培養検体からC. aurisを15分で同定するため、特別に開発された初の迅速ラテラルフロー免疫測定法です。発表されたデータでは、多様な分離株における参照法と100％の一致が示されており、アウトブレイク調査や感染制御の役割を裏付けています。NG-TEST® Acineto-5®は、Acinetobacter検体から直接5つの主要カルバペネマーゼファミリー（OXA-23-like、
More news about: Hardy Diagnostics
Feb 18, 2026, 07:43 ET FDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens
Antimicrobial Resistance (AMR), NG Biotech, in partnership with Hardy Diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designations to two rapid diagnostic assays: NG-TEST® Candida auris and NG-TEST® Acineto-5®.
More news about: Hardy Diagnostics
Feb 18, 2026, 07:43 ET La FDA califica como dispositivo innovador dos pruebas dirigidas a patógenos resistentes a los fármacos
antimicrobianos (RAM), NG Biotech, en colaboración con Hardy Diagnostics, anunció hoy que la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) ha otorgado la designación de dispositivo innovador a dos ensayos de diagnóstico rápido: NG-TEST®Candida auris y NG-TEST®Acineto-5®. Esta designación
More news about: Hardy Diagnostics
Feb 17, 2026, 13:31 ET Kung Fu Tea and ADVANCED® Launch HYDRATION+ Immunity* for Lunar New Year
Amazon."Partnering with an iconic brand like Kung Fu Tea allows us to bridge the gap between lifestyle, culture, and functional nutrition," added Richard Ng, Director of Brand Partnerships at ADVANCED®. "This is only the first in a series of innovations we have planned."Nationwide Sampling EventTo
More news about: Kung Fu Tea
Feb 17, 2026, 06:00 ET Zensai Executives Join Global AI Leaders on the HumanX 2026 Stage
transformation across AI. The speaker roster features AI luminaries shaping the future of AI including Bret Taylor, Chairman of the OpenAI Board; Andrew Ng, Founder and CEO of DeepLearning.AI; and May Habib, CEO of Writer, who will share insights on how organizations can lead in the age of artificial intelligence."We're
More news about: Zensai
Feb 16, 2026, 09:03 ET Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
standard-of-care (SOC) 68Ga-PSMA-11 in 50 patients with biochemical recurrence (BCR) of prostate cancer (with prostate-specific antigen [PSA] 0.2-0.75 ng/mL) following radical prostatectomy who were candidates for curative salvage therapy.64Cu-SAR-bisPSMA positron emission tomography
More news about: Clarity Pharmaceuticals
Feb 12, 2026, 17:55 ET Greenberg Traurig Attorneys, Practices Recognized in 2026 Chambers Global Guide
Alfred Ng (Projects & Infrastructure: International)
More news about: Greenberg Traurig, LLP
Feb 10, 2026, 17:00 ET Prominent Energy Transition and Carbon Capture Leader Myles Culhane Joins Greenberg Traurig in Sacramento
Alfred Ng in
More news about: Greenberg Traurig, LLP
Feb 10, 2026, 14:39 ET DATAMARK Technologies Welcomes Industry Veteran Mike Nobers as Channel Partner Manager
Technologies' partner network, ensuring that partners are equipped to deliver high-quality Geographic Information Systems (GIS) and Next Generation 9-1-1 (NG9-1-1) solutions to public safety organizations nationwide. His leadership will deepen collaboration with integrators and technology providers, elevate partner
More news about: DATAMARK Technologies
Feb 10, 2026, 09:10 ET Qnovia's Inhaled Nicotine Replacement Therapy Delivers Positive Results in First Human Study
uptake, an essential factor for effective craving control and smoking cessation. Reaching peak blood levels in 7 minutes with just 10 puffs (Cmax 8.7 ng/mL), demonstrating a Tmax comparable to combustible cigarettes of ~6 minutes, significantly outperforming authorized legacy nicotine replacement therapiesMeaningful
More news about: Qnovia, Inc.